Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   14 Feb Valentine-Pharming Fridayday

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,930   +0,004   (+0,38%) Dagrange 0,921 - 0,936 4.218.904   Gem. (3M) 6,7M

14 Feb Valentine-Pharming Fridayday

Volgen
1.182 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 60 »» | Laatste | Omlaag ↓
  1. [verwijderd] 14 februari 2014 16:33
    Sobi has continued its roll-out of Ruconest® and the drug is now available in the European territory. To date approximately 400-500 angioedema attacks have been treated with Ruconest® since the launch. It is important to remember that every patient can have several attacks per year. Market share for Ruconest® varies significantly between countries. The highest market share during 2012 was reached in Finland (15%) which is expected to grow to a 30% market share during 2013. We expect a continuous increase in patients using Ruconest® during 2013, especially in Central and Eastern European Countries, which will be made possible by the recently obtained pricing and market access approvals in some of these countries. The market access process continues across European markets using the various country specific procedures to obtain reimbursements and to make the product administratively available under the various national and regional healthcare systems.
    ? To accelerate acceptance of Ruconest® in the key EU markets during the course of 2013, Sobi have recently re-aligned their commercial organisation and have initiated specific in-market actions. After a slow 2012, we therefore now expect a continuous increase in patients using Ruconest® during 2013.
  7. [verwijderd] 14 februari 2014 16:34
    quote:

    PharmOptimist schreef op 14 februari 2014 16:33:

    Sobi has continued its roll-out of Ruconest® and the drug is now available in the European territory. To date approximately 400-500 angioedema attacks have been treated with Ruconest® since the launch. It is important to remember that every patient can have several attacks per year. Market share for Ruconest® varies significantly between countries. The highest market share during 2012 was reached in Finland (15%) which is expected to grow to a 30% market share during 2013. We expect a continuous increase in patients using Ruconest® during 2013, especially in Central and Eastern European Countries, which will be made possible by the recently obtained pricing and market access approvals in some of these countries. The market access process continues across European markets using the various country specific procedures to obtain reimbursements and to make the product administratively available under the various national and regional healthcare systems.
    ? To accelerate acceptance of Ruconest® in the key EU markets during the course of 2013, Sobi have recently re-aligned their commercial organisation and have initiated specific in-market actions. After a slow 2012, we therefore now expect a continuous increase in patients using Ruconest® during 2013.
    wil je bij zulke berichten een datum plaatsen, CRUCIAAL.
1.182 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 60 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. DWS meldt groter belang in Pharming
  2. Morgan Stanley groter in Pharming
  3. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  4. RBC verhoogt koersdoel Pharming fors
  5. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  6. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  7. Pharming brengt bod op Abliva AB uit
  8. Moeizame week voor financials
  9. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  10. Fundlogic verkleint belang in Pharming